Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06813014 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pharmacogenetics of Response to Sitagliptin (PRS)

Study acronym: PRS
StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Jan 2026 to Dec 2026
    • Primary completion date: Dec 2031 to Nov 2031
    v4
  2. Primary completion date: Aug 2030 to Dec 2031
    • Start date: Sep 2025 to Jan 2026
    • Study completion date: Aug 2031 to Dec 2032
    v3
  3. Start date: Jun 2025 to Sep 2025
    • Primary completion date: May 2030 to Aug 2030
    • Study completion date: May 2031 to Aug 2031
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a research study to find out how different people respond to a medication called sitagliptin. Sitagliptin is an FDA approved medication that is used to treat diabetes. We are asking for healthy, non-diabetic volunteers to participate in this 7-week study. If you agree to participate, you will take part in 2 clinic visits that are 4-6 weeks apart. At the clinic visits you will have an oral glucose tolerance test (OGTT) and other blood tests to see how your body processes glucose (sugar). An OGTT is a test in which your drink glucose and then blood samples are taken afterward at specific time points to measure glucose and insulin in your blood. Each clinic visit will last about 5 hours.
Trial Details
NCT Number NCT06813014
Lead Sponsor University of Maryland, Baltimore
Conditions
(from sponsor)		 Diabetes
Related terms Diabetes Mellitus
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov